Introduction of Paramivir Sodium Chloride Injection

Palamivir injection has been researched and developed for 8 years. All clinical studies were completed on 20 1 1, and 20 12+02 was approved for marketing through the technical evaluation of the drug testing center. Paramivir injection has a better curative effect than oseltamivir phosphate, and can effectively fight oseltamivir-resistant influenza virus. The dosage form is injection, which is suitable for treating critically ill patients with influenza and patients with poor curative effect of other neuraminidase inhibitors. On April 5, 20 13, peramivir sodium chloride injection was approved for marketing by China Food and Drug Administration.